Hutchison MediPharma Starts Phase III Trial of Cancer Drug

Last week, Hutchison MediPharma, a division of Chi-Med, dosed the first patient in a China Phase III clinical trial of fruquintinib (HMPL-013), a treatment for solid tumor cancers. The trial will enroll more than 400 patients with advanced colorectal cancer who have already failed two previous antineoplastic therapies. In 2013, Hutchison MediPharma out-licensed China rights for fruquintinib to Lilly in a deal worth up to $86.5 million in upfront and milestone payments. More details.... Stock Symbols: (AIM: HCM) (NYSE: LLY) Share this with colleagues: // //